U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Bodyhealth.com, LLC - 610728 - 12/17/2021
  1. Warning Letters

CLOSEOUT LETTER

Bodyhealth.com, LLC MARCS-CMS 610728 —

Delivery Method:
VIA Electronic Mail
Reference #:
21-HAFE4-WL-01
Product:
Dietary Supplements
Recipient:
Recipient Name
Mr. David I. Minkoff
Recipient Title
Owner
Bodyhealth.com, LLC

745 Main St.
Dunedin, FL 34698-5018
United States

drminkoff@bodyhealth.com
Issuing Office:
Division of Human and Animal Food Operations East IV

United States

Dear Mr. Minkoff:

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to 21-HAFE4-WL-01, dated December 09, 2020. It appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Kind regards,
/S/
Pearl Lopina
Director of Compliance Branch
OHAFO, Division IV East

Back to Top